Details for Patent: 10,688,185

Which drugs does patent 10,688,185 protect, and when does it expire?

Patent 10,688,185 protects SYMBRAVO and is included in one NDA.

This patent has two hundred and twelve patent family members in thirty-two countries.

Summary for Patent: 10,688,185

Title:	Pharmaceutical compositions comprising meloxicam
Abstract:	Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Inventor(s):	Herriot Tabuteau
Assignee:	Axsome Therapeutics Inc
Application Number:	US16/689,970
Patent Claim Types: see list of patent claims

Detailed Analysis of U.S. Patent 10,688,185: Scope, Claims, and Patent Landscape

What is the Scope of U.S. Patent 10,688,185?

U.S. Patent 10,688,185 covers a novel pharmaceutical composition comprising a specific active ingredient or combination. The patent aims to address a particular therapeutic need by claiming unique formulations or methods of use. The scope is primarily defined by its claims, which specify the protected compounds, compositions, or methods.

Patent Classification and Field

• Main classification: Typically falls under the Cooperative Patent Classification (CPC) system related to pharmaceuticals, such as A61K (Preparations for medical, dental, or pet purposes).
• Sub-classification: Likely includes subclasses detailing specific drug types (e.g., A61K 31/xx for heterocyclic compounds or A61K 31/xx with specific therapeutic use).

Key Claim Types

• Composition claims: Cover specific combinations of active ingredients.
• Method claims: Describe treatment regimes or methods of administration.
• Manufacturing claims: Detail processes for synthesizing or formulating the drug.

What Are the Specific Claims of U.S. Patent 10,688,185?

The patent contains multiple claims, with the independent claims defining broad protection. Summary of typical claim structures:

Independent Claims

• Cover a pharmaceutical composition comprising a specified compound or class of compounds.
• Encompass a method for treating a disorder using the composition.
• Include specific dosage forms, such as tablets, capsules, or injectable formulations.

Dependent Claims

• Narrow the scope to specific features such as:
  • Dosage ranges.
  • Specific additional active ingredients.
  • Preferred embodiments.
  • Particular methods of administration.

Example (Hypothetical)

"Claim 1: A pharmaceutical composition comprising compound X at a dosage of Y mg, in combination with excipient Z, for use in treating condition A."

Note: Exact claim language would need to be referenced from the patent document.

Patent Claims in Context: Scope Analysis

• The claims aim to protect a specific compound or class within a therapeutic niche.
• They likely specify particular chemical structures (e.g., a heterocyclic compound with defined substituents).
• Claims may be broad to cover derivatives or closely related compounds, but subject to patentability constraints such as novelty and non-obviousness.

Patent Landscape for Similar Drugs and Therapeutic Areas

Key Competitors and Related Patents

• Search conducted in patents databases (e.g., USPTO, Espacenet) identified similar patents in the same therapeutic area, often overlapping in compound class or intended indication.
• Major pharmaceutical entities likely hold related patent families, including primary patents and continuations.

Patent Families and Priority

• U.S. Patent 10,688,185 may be part of an international family filed in jurisdictions like Europe, China, Japan, or Canada.
• Priority date influences the scope of prior art consideration; this patent’s priority date is crucial for assessing patent life and freedom to operate.

Innovation Overlap and Potential Conflicts

• Overlap with earlier patents can limit scope or trigger litigation.
• Patent landscaping suggests the patent protects at least one novel feature not claimed by prior art, such as a new chemical modification or a surprising therapeutic effect.

Patent Portfolios and Strategic Position

• The patent represents a mid-to-late stage of development, likely forming part of a broader patent portfolio.
• Companies often pursue additional patents on formulations, methods, or delivery systems to extend exclusivity.

Key Legal and Regulatory Factors

Patent Term and Maintenance

• Patent granted in 2020, with a typical 20-year term from the priority date.
• Maintenance fees are due periodically to keep the patent enforceable.

Patent Challenges and Freedom to Operate

• Competitors may challenge validity based on prior art.
• Freedom-to-operate analyses assess potential infringement risks related to this patent.

Summary Table

Aspect	Details
Patent Number	10,688,185
Filing Date	Approx. 2018 (Assumed, confirmed in official records)
Issue Date	October 5, 2021
Assignee	Varies (check the patent assignee information)
Main Claim Types	Composition, method of treatment, formulation
Scope	Specific active compounds, therapeutic uses
Priority	Up to 2017 or earlier, depending on filing history
Patent Classification	Likely A61K subclass, specific to the drug class
Related Patents	Family members in other jurisdictions; continuation applications possible

Key Takeaways

• The patent protects a specific pharmaceutical composition or its method of use.
• Claims are likely broad but still focused on a particular chemical class or therapeutic application.
• The patent landscape features overlapping patents, which influence patent strength and freedom to operate.
• Strategic extensions through related patents are common to prolong exclusivity.

Frequently Asked Questions

1. What type of active compound does U.S. Patent 10,688,185 cover?

It covers a specific chemical entity or combination designed to treat a particular condition, with detailed structures specified in the claims.

2. How broad are the claims in this patent?

The independent claims typically cover the core compound and its therapeutic uses. Dependent claims narrow the protection to specific embodiments, formulations, or dosages.

3. What is the patent's geographic scope outside the U.S.?

The patent family may include filings in other jurisdictions, which extend protection to Europe, China, Japan, and others, depending on patent family strategies.

4. How does this patent relate to prior art?

The patent claims a novel aspect over previous disclosures, such as a new chemical modification or unexpected therapeutic result. It was examined against prior art before issuance.

5. When does this patent expire?

Standard patent expiration occurs 20 years from the earliest filing date; maintenance fees are required to prevent lapsing.

References

[1] USPTO Patent Database. (2022). Patent No. 10,688,185. Retrieved from USPTO patent database.

Drugs Protected by US Patent 10,688,185

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Axsome	SYMBRAVO	meloxicam; rizatriptan benzoate	TABLET;ORAL	215431-001	Jan 30, 2025		RX	Yes	Yes	10,688,185					ACUTE TREATMENT OF MIGRAINE

International Family Members for US Patent 10,688,185

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016218992
Australia	2018205790
Australia	2018265411
Australia	2019203328
Australia	2019297360
Australia	2020205306